 SAN DIEGO, July 27, 2021 GLOBE NEWSWIRE -- Cidara Therapeutics, Inc. NASDAQ: CDTX, a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, today announced that it will present clinical and pre-clinical data, including updated analyses from the Phase 2 STRIVE study and an in vitro evaluation of rezafungin activity against Candida and Aspergillus spp. isolates collected in Asia-Pacific countries, in two presentations at the International Society for Human and Animal Mycology ISHAM Asia Congress taking place virtually from August 6-8, 2021. 